



ASX Announcement

23 April 2019

Additional Information on Creso's Licence to Import its First Medicinal Cannabis Product into Brazil

Creso Pharma Limited (ASX:CPH) (the "Company" or "Creso"), wishes to provide additional information regarding its license to import its first medicinal cannabis product into Brazil, as announced to the ASX on 18 April 2019.

Creso and its marketing partner, SIN Solution, received regulatory clearance in the form of an import license ("License") from Brazilian health regulatory agency ANVISA for the importation of Creso's medicinal cannabis product cannaQIX® 50.

The License provides for access to Creso's cannaQIX® 50 on a patient name basis and is valid for a year, subject to regulatory renewals which is common practice for licenses of this nature.

Creso's cannaQIX 50® product has been developed to help patients suffering from chronic pain and, in particular, chronic pain related to neuropathic diseases such as multiple sclerosis, Parkinsons and cancer.

Initial focus of marketing, sales and patient support activities will be in the cities of Sao Paulo, Rio de Janeiro, and Curitiba (Parana), which have a combined population of over 22 million people. The main targets are doctors working in the fields of oncology and neurology with an initial estimated addressable market of over 50,000 patients.

cannaQIX®50 is Creso's first product to be made available in Brazil, and follows the product's successful launch in New Zealand last year.

Ends

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

Media Enquiries

Julia Maguire | The Capital Network

E: julia@thecapitalnetwork.com.au

P: +61 419 815 386

**About Creso Pharma**

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp de-rived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.